LUCENTIX develops a new biosensor technology that allows patients to measure precise concentrations of analytes in a single drop of blood or saliva using a low-cost handheld device giving laboratory-quality results. Measurements that today require sample shipping, skilled personnel, tedious sample preparation and a fully equipped laboratory, can be done by patients themselves within minutes.

Read More


New publication in Nature Communications

New molecular mechanism developed by our team expands the reach of the Lucentix biosensor technology.

Our team has published an article in the July 2015 issue of Nature Communications describing a new biosensor mechanism that expands the sensing principle to different targets, including large proteins. The publication has received widespread media attention including a feature in the The Times.

Read an article on the EPFL website here.

Read the publication in Nature Communications.

Lucentix' technology in the Washington Post

Lucentix' technology has been featured in the Washington Post.

The Washington Post has reported on our technology in their July 22 issue.

Read the article here.

Lucentix wins CHF 100'000 in the Venture Kick final

Lucentix received CHF 130 000, the maximum funding granted by Venture Kick.

Venture Kick announced last week that the EPFL spin-off Lucentix is one of the winners of the final stage of Venture Kick and will receive CHF 100'000 to support their venture. The startup has already won CHF 30'000 in the first two stages of the competition.

Read the full story here.


LUCENTIX is a young start-up at the École Polytechnique Fédérale de Lausanne (EPFL). The technology underlying the biosensors was developed by Rudolf Griss and Alberto Schena in the course of their PhD studies with Prof. Kai Johnsson.




If you would like to learn more or are looking for partnerships or investment opportunities, please contact us using the form below.


Lucentix SA
EPFL Innovation Park, Bâtiment C
CH-1015 Lausanne